Gene therapy breakthrough? new treatment aims to fix sickle cell at the source
Disease control
Recruiting now
This early-stage trial is testing a new gene therapy called nula-cel for people with severe sickle cell disease. The therapy modifies a patient's own blood stem cells to produce normal hemoglobin instead of sickle hemoglobin. About 15 participants aged 12 to 40 will receive the t…
Phase: PHASE1, PHASE2 • Sponsor: Kamau Therapeutics • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC